Treatment outcomes for Mycobacterium avium complex: a systematic review and meta-analysis
- 28 February 2014
- journal article
- review article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 33 (3), 347-358
- https://doi.org/10.1007/s10096-013-1962-1
Abstract
To evaluate the existing evidence regarding treatment regimens for Mycobacterium avium complex (MAC), a systematic review of the available therapeutic studies was conducted to assess treatment outcomes. A random-effects meta-analysis was used to assess treatment outcomes. Subgroup analyses were also conducted by separating studies based on each characteristic independently. Twenty-eight trials met the inclusion criteria. Our meta-analysis showed that the estimated pooled treatment success rate for patients with MAC disease was 39 % [95 % confidence interval (CI) 38-41 %]. The rates of failure, relapse, death, and default were 27 % (95 % CI 25-29 %), 6 % (95 % CI 5-7 %), 17 % (95 % CI 15-18 %), and 12 % (95 % CI 11-13 %), respectively. The proportion of patients treated successfully did not differ significantly on the basis of the study characteristics. However, studies with treatment regimens containing macrolides had significantly higher pooled success proportions (42 %, 95 % CI 40-44 %) than that of other studies (28 %, 95 % CI 24-32 %). Substantial heterogeneity in the study characteristics prevented more conclusive determination of what factors had the greatest effect on the proportion of patients that achieve treatment success and limited the validity of this analysis. This review underscored the importance of strong patient support and treatment follow-up systems to develop successful MAC treatment programs.This publication has 44 references indexed in Scilit:
- Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapyThorax, 2008
- Measuring inconsistency in meta-analysesBMJ, 2003
- First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutolThorax, 2001
- A Randomized, Double-Blind Trial Comparing Azithromycin and Clarithromycin in the Treatment of Disseminated Mycobacterium avium Infection in Patients with Human Immunodeficiency VirusClinical Infectious Diseases, 2000
- Early Results (at 6 Months) with Intermittent Clarithromycin-Including Regimens for Lung Disease Due to Mycobacterium avium ComplexClinical Infectious Diseases, 2000
- Prospective Randomized Trial of Four Three‐Drug Regimens in the Treatment of DisseminatedMycobacterium aviumComplex Disease in AIDS Patients: Excess Mortality Associated with High‐Dose ClarithromycinClinical Infectious Diseases, 1999
- Rifabutin Versus Placebo in Combination with Three Drugs in the Treatment of Nontuberculous Mycobacterial Infection in Patients with AIDSClinical Infectious Diseases, 1996
- The Individual Microbiologic Effect of Three Antimycobacterial Agents, Clofazimine, Ethambutol, and Rifampin, on Mycobacterium avium Complex Bacteremia in Patients with AIDSThe Journal of Infectious Diseases, 1994